June 20, 2017June 20, 2017
Taliglucerase Alfa Therapy Seen as Safe and Effective for Children with Gaucher Disease Type 1, Review Finds

The plant–based enzyme Elelyso (taliglucerase alfa), developed by Protalix and Pfizer as an intravenous enzyme replacement therapy (ERT), is ... Read more
June 15, 2017June 15, 2017
Gaucher Initiative in Egypt, UnitedHealth Group Recognized at Project HOPE’s Annual NYC Gala

Project HOPE has named UnitedHealth Group and the Gaucher Initiative in Egypt the recipients of its 2017 Global Health Awards. The ... Read more
June 13, 2017June 13, 2017
Introduction of Enzyme Replacement Therapy with Cerezyme Has Significantly Decreased Severe GD1 Complications, Study Shows

The presence of severe complications of Gaucher disease type 1 (GD1) at the time a patient starts treatment has ... Read more
June 8, 2017
Different Mutations in Gaucher Disease May Be Linked to Development of Parkinson’s

New research reports that the difference in severity of Parkinson’s symptoms in patients with Gaucher disease may be due ... Read more
June 1, 2017
England’s National Health Service to Make Cerdelga Available as Gaucher Therapy

Cerdelga (eliglustat) will become the first oral treatment that England’s National Health Service (NHS) makes available to patients with Gaucher ... Read more
May 23, 2017May 23, 2017
Cerdelga Improves Gastrointestinal Symptoms in GD Patient, Korean Case Report Shows

Cerdelga (eliglustat tartrate) can be effective in treating gastrointestinal lesions in patients with Gaucher disease (GD), according to a ... Read more
May 18, 2017
Earlier Diagnosis of Gaucher in Children Reduces Incidence of Severe Disease, Study Says

The early diagnosis of children with Gaucher disease eligible for enzyme replacement therapy (ERT) helps decrease the incidence of severe ... Read more
May 16, 2017May 16, 2017
Good Start Genetics’ VeriYou to Offer Ashkenazi Jewish Carrier Screening Test for Multiple Disorders

Good Start Genetics is expanding VeriYou, its physician-ordered carrier screening tests, to include screening for Gaucher disease and 18 other inherited ... Read more
May 11, 2017May 11, 2017
Sales of Protalix’s Gaucher Therapy Elelyso Increase Substantially This Year

The sales of Elelyso for the treatment of Gaucher disease have increased significantly so far this year, Protalix BioTherapeutics ... Read more
May 9, 2017
The Assistance Fund Now Provides Financial Help for Gaucher Patients, Families

The Assistance Fund is now providing financial assistance to help patients living with Gaucher disease (GD). The new fund will ... Read more
May 4, 2017May 4, 2017
Health Canada Approves Sanofi Genzyme’s Cerdelga to Treat Gaucher Disease Type 1

Health Canada has approved Cerdelga (eliglustat capsules), manufactured by Sanofi Genzyme, for treating Gaucher disease type 1 (GD1) — three years after ... Read more
April 27, 2017
PPMI Clinical Trial Seeks to Uncover Link Between GBA Mutations and Parkinson’s

The National Gaucher Foundation has endorsed a clinical study designed to identify biomarkers of Parkinson’s disease (PD), and to ... Read more

Taliglucerase Alfa Therapy Seen as Safe and Effective for Children with Gaucher Disease Type 1, Review Finds

The plant–based enzyme Elelyso (taliglucerase alfa), developed by Protalix and Pfizer as an intravenous enzyme replacement therapy (ERT), is seen as effective and safe for the treatment of children ... Read more

June 15, 2017June 15, 2017

Gaucher Initiative in Egypt, UnitedHealth Group Recognized at Project HOPE’s Annual NYC Gala

Project HOPE has named UnitedHealth Group and the Gaucher Initiative in Egypt the recipients of its 2017 Global Health Awards. The awards, handed out during the nonprofit organization’s June 13 annual ... Read more

June 13, 2017June 13, 2017

Introduction of Enzyme Replacement Therapy with Cerezyme Has Significantly Decreased Severe GD1 Complications, Study Shows

The presence of severe complications of Gaucher disease type 1 (GD1) at the time a patient starts treatment has steadily dropped since the introduction of enzyme replacement therapy with ... Read more

June 8, 2017

Different Mutations in Gaucher Disease May Be Linked to Development of Parkinson’s

New research reports that the difference in severity of Parkinson’s symptoms in patients with Gaucher disease may be due to the difference in the genetic makeup of cells in ... Read more

June 1, 2017

England’s National Health Service to Make Cerdelga Available as Gaucher Therapy

Cerdelga (eliglustat) will become the first oral treatment that England’s National Health Service (NHS) makes available to patients with Gaucher disease. At the moment, the only treatment the health service ... Read more

May 23, 2017May 23, 2017

Cerdelga Improves Gastrointestinal Symptoms in GD Patient, Korean Case Report Shows

Cerdelga (eliglustat tartrate) can be effective in treating gastrointestinal lesions in patients with Gaucher disease (GD), according to a clinical case published in BMC Medical Genetics. This finding supports the ... Read more

May 18, 2017

Earlier Diagnosis of Gaucher in Children Reduces Incidence of Severe Disease, Study Says

The early diagnosis of children with Gaucher disease eligible for enzyme replacement therapy (ERT) helps decrease the incidence of severe complications and allows patients to have improved development, according to ... Read more

May 16, 2017May 16, 2017

Good Start Genetics’ VeriYou to Offer Ashkenazi Jewish Carrier Screening Test for Multiple Disorders

Good Start Genetics is expanding VeriYou, its physician-ordered carrier screening tests, to include screening for Gaucher disease and 18 other inherited genetic disorders that are especially prevalent among Ashkenazi Jews, or ... Read more

May 11, 2017May 11, 2017

Sales of Protalix’s Gaucher Therapy Elelyso Increase Substantially This Year

The sales of Elelyso for the treatment of Gaucher disease have increased significantly so far this year, Protalix BioTherapeutics announced in a press release. Protalix BioTherapeutics is an Israel-based pharmaceutical company ... Read more

May 9, 2017

The Assistance Fund Now Provides Financial Help for Gaucher Patients, Families

The Assistance Fund is now providing financial assistance to help patients living with Gaucher disease (GD). The new fund will provide GD patients and families with financial aid for copayments, ... Read more

May 4, 2017May 4, 2017

Health Canada Approves Sanofi Genzyme’s Cerdelga to Treat Gaucher Disease Type 1

Health Canada has approved Cerdelga (eliglustat capsules), manufactured by Sanofi Genzyme, for treating Gaucher disease type 1 (GD1) — three years after the U.S. Food and Drug Administration gave its blessing to ... Read more

April 27, 2017

PPMI Clinical Trial Seeks to Uncover Link Between GBA Mutations and Parkinson’s

The National Gaucher Foundation has endorsed a clinical study designed to identify biomarkers of Parkinson’s disease (PD), and to evaluate the connection between this disease and the occurrence of ... Read more